-
-
-
-
-
-
-
Gossamer Bio reports 90.5% participation in convertible note exchange
-
-
-
-
-
-
-
Leerink Partners Downgrades Gossamer Bio Inc. (GOSS) to Market Perform
-
-
-
-
-
-
-
Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald
-
-
-
-
-
-
-
UBS Upgrades Gossamer Bio Inc. (GOSS) to Buy
-
-
-
-
-
-
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
442,126 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

